Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s
Executive Summary
Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.